TY - JOUR
T1 - Sex-specific progression of Parkinson's disease
T2 - A longitudinal mixed-models analysis
AU - Hanff, Anne Marie
AU - McCrum, Christopher
AU - Rauschenberger, Armin
AU - Aguayo, Gloria A.
AU - Pauly, Claire
AU - Jónsdóttir, Sonja R.
AU - Tsurkalenko, Olena
AU - Zeegers, Maurice P.
AU - Leist, Anja K.
AU - Krüger, Rejko
AU - NCER-PD Consortium
N1 - Funding:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The National Centre of Excellence in Research on Parkinson’s Disease (NCER-PD) is funded by the Luxembourg National
Research Fund (FNR/NCER13/BM/11264123). The work was further supported by the PEARL program (FNR/P13/6682797 to RK).
PY - 2025/6
Y1 - 2025/6
N2 - Background: Despite its relevance, the clinical progression of motor- and non-motor symptoms associated with Parkinson's disease (PD) is poorly described and understood, particularly in relation to sex-specific differences in clinical progression. Objective: Identification of differential aspects in disease progression in men and women with PD. Methods: Linear mixed-model analyses of 802 people with typical PD from the Luxembourg Parkinson's study's prospective cohort (median time of follow-up = three years). We estimated the effect of time and its moderation by sex (alpha ≤ 0.05), including confidence intervals, for the following outcomes: MDS-UPDRS I-IV, Starkstein Apathy Scale, Beck Depression Inventory, Montreal Cognitive Assessment (MoCA), Sniffin’ sticks, bodily discomfort, rapid eye movement sleep behavior disorder questionnaire, PD Sleep Scale (PDSS), Munich Dysphagia Test-PD, Functional Mobility Composite Score, and the MDS-based tremor and postural instability and gait disturbances scale. In addition, the marginal means illustrated the symptoms’ trajectories in men and women. Men and women had similar age. Results: Overall, we observed a slower progression (interaction effect) in women compared to men, especially for MoCA (−0.159, 95%CI [−0.272, −0.046], p = 0.006), PDSS (−0.716, 95%CI [−1.229, −0.203], p = 0.006), PIGD (0.133, 95%CI [0.025 0.241], p = 0.016), and MDS-UPDRS II (0.346, 95%CI [0.120, 0.572], p = 0.003). The finding for MDS-UPDRS II was significant (FWER of 5%) after adjustment for multiple comparisons (Bonferroni-Holm). Conclusions: Next to the further exploration of sex-specific progression, interventions, proactive monitoring and communication strategies tailored to the symptoms progression and needs of men and women need to be developed.
AB - Background: Despite its relevance, the clinical progression of motor- and non-motor symptoms associated with Parkinson's disease (PD) is poorly described and understood, particularly in relation to sex-specific differences in clinical progression. Objective: Identification of differential aspects in disease progression in men and women with PD. Methods: Linear mixed-model analyses of 802 people with typical PD from the Luxembourg Parkinson's study's prospective cohort (median time of follow-up = three years). We estimated the effect of time and its moderation by sex (alpha ≤ 0.05), including confidence intervals, for the following outcomes: MDS-UPDRS I-IV, Starkstein Apathy Scale, Beck Depression Inventory, Montreal Cognitive Assessment (MoCA), Sniffin’ sticks, bodily discomfort, rapid eye movement sleep behavior disorder questionnaire, PD Sleep Scale (PDSS), Munich Dysphagia Test-PD, Functional Mobility Composite Score, and the MDS-based tremor and postural instability and gait disturbances scale. In addition, the marginal means illustrated the symptoms’ trajectories in men and women. Men and women had similar age. Results: Overall, we observed a slower progression (interaction effect) in women compared to men, especially for MoCA (−0.159, 95%CI [−0.272, −0.046], p = 0.006), PDSS (−0.716, 95%CI [−1.229, −0.203], p = 0.006), PIGD (0.133, 95%CI [0.025 0.241], p = 0.016), and MDS-UPDRS II (0.346, 95%CI [0.120, 0.572], p = 0.003). The finding for MDS-UPDRS II was significant (FWER of 5%) after adjustment for multiple comparisons (Bonferroni-Holm). Conclusions: Next to the further exploration of sex-specific progression, interventions, proactive monitoring and communication strategies tailored to the symptoms progression and needs of men and women need to be developed.
KW - cohort studies
KW - epidemiology
KW - neurodegenerative disease
KW - patient reported outcome measures
KW - sex differences
KW - women
UR - https://www.scopus.com/pages/publications/105009383665
UR - https://pubmed.ncbi.nlm.nih.gov/40388933/
U2 - 10.1177/1877718X251339201
DO - 10.1177/1877718X251339201
M3 - Article
C2 - 40388933
AN - SCOPUS:105009383665
SN - 1877-7171
VL - 15
SP - 805
EP - 818
JO - Journal of Parkinson's Disease
JF - Journal of Parkinson's Disease
IS - 4
ER -